These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 36869384)

  • 1. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
    Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
    Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell RNA sequencing reveals microenvironmental infiltration in non-small cell lung cancer with different responses to immunotherapy.
    Hu X; Wu Y; Wang L; Yang F; Ye L; Chen X; Song X; Wei P
    J Gene Med; 2024 Sep; 26(9):e3736. PubMed ID: 39228151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADGRE5-centered Tsurv model in T cells recognizes responders to neoadjuvant cancer immunotherapy.
    Li J; Meng Z; Cao Z; Lu W; Yang Y; Li Z; Lu S
    Front Immunol; 2024; 15():1304183. PubMed ID: 38343549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
    Zhang J; Ji Z; Caushi JX; El Asmar M; Anagnostou V; Cottrell TR; Chan HY; Suri P; Guo H; Merghoub T; Chaft JE; Reuss JE; Tam AJ; Blosser RL; Abu-Akeel M; Sidhom JW; Zhao N; Ha JS; Jones DR; Marrone KA; Naidoo J; Gabrielson E; Taube JM; Velculescu VE; Brahmer JR; Housseau F; Hellmann MD; Forde PM; Pardoll DM; Ji H; Smith KN
    Clin Cancer Res; 2020 Mar; 26(6):1327-1337. PubMed ID: 31754049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
    Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
    Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
    Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
    BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Zhang H; Liu Z; Wen H; Guo Y; Xu F; Zhu Q; Yuan W; Luo R; Lu C; Liu R; Gu J; Ge D
    Cancer Immunol Immunother; 2022 Oct; 71(10):2511-2522. PubMed ID: 35278107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 10. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer.
    Cai W; Jing M; Gu Y; Bei T; Zhao X; Chen S; Wen J; Gao J; Wu C; Xue Z
    Front Immunol; 2022; 13():984666. PubMed ID: 36275670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
    Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
    Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
    Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
    Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.
    Xiao B; Li G; Gulizeba H; Liu H; Sima X; Zhou T; Huang Y
    J Transl Med; 2024 May; 22(1):442. PubMed ID: 38730286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
    Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
    Front Immunol; 2021; 12():756722. PubMed ID: 34804043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of circulating tumor cells in monitoring the efficacy of neoadjuvant immunotherapy for non-small cell lung cancer].
    Li YJ; Chen H; Liao JF; Yuan JL; Chen T; Zhu J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Feb; 55(2):233-238. PubMed ID: 34645185
    [No Abstract]   [Full Text] [Related]  

  • 19. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.
    Wang S; Yuan P; Mao B; Li N; Ying J; Tao X; Tang W; Zhang L; Geng X; Zhang F; Xue Q; Wu L; Zhang H; Gao S; He J
    NPJ Precis Oncol; 2022 Jan; 6(1):2. PubMed ID: 35027673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.